Mable is a San Francisco-based, patent-pending genomics-powered telehealth clinic focused specifically on migraine care. The company uses an individual’s DNA to create preventive and acute plans customized to that person’s unique needs. With the right plan in place, Mable delivers appropriate medication straight to patients’ doors and provides ongoing expert care in the comfort of their homes. The company is led by co-founder & CEO Roman Rothaermel. Mable raised $3.2M in seed funding and intends to use the proceeds to expand operations and its business reach. The company previously received pre-seed funding from Y Combinator and Illumina, Inc.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2022